Sun Pharma Gains 9% After $11.75 Billion Organon Acquisition: What Investors Should Know
India's largest drugmaker makes its biggest-ever bet. Here is what the numbers say and what comes next.
Sun Pharmaceutical Industries has agreed to acquire Organon & Co. in an all-cash deal at an enterprise valuation of $11.75 billion ($14 per Organon share). The combined entity will generate ~$12.4 billion in revenue, rank among the top 25 global pharma companies, become a top-3 women's health player, and be the 7th largest biosimilar company globally. Sun Pharma shares hit an intraday high of ₹1,766.65 (+9.06%) on April 27, 2026. Post-deal leverage is 2.3x net debt/EBITDA, with EBITDA and cash flow set to nearly double.
Why This Sun Pharma Organon Deal Matters
India's largest drugmaker, Sun Pharmaceutical Industries, has announced the acquisition of Organon & Co. in an all-cash deal at an enterprise valuation of $11.75 billion, one of the largest outbound acquisitions ever by an Indian company. Organon shareholders will receive $14.00 per share in cash. The transaction marks a major strategic shift for Sun Pharma as it deepens its global presence in branded medicines, women's health, and biosimilars.
Once completed, the combined business is expected to generate around $12.4 billion in revenue, placing Sun Pharma among the top 25 pharmaceutical companies globally. It also significantly improves the company's position in women's health and biosimilars, two of the fastest-growing segments in global healthcare.
Organon was created as a spin-off from Merck & Co. in 2021 and operates across women's health, legacy branded medicines, and biosimilars, with a commercial presence in 150 countries. That portfolio gives Sun Pharma access to products, markets, and channels that could take years to build organically.
What Organon Brings to Sun Pharma
The biggest attraction is diversification across three meaningful areas.
Women's health is Organon's core franchise, a category with steady long-term demand and resilient pricing in many markets. The combined entity is expected to become a top-3 company in global women's health.
Biosimilars are complex medicines modelled after biological drugs and represent a major global growth opportunity. Through this acquisition, Sun Pharma becomes the 7th-largest global biosimilar player.
Geographic reach is the third pillar. Organon has commercial operations across 140+ countries, including 18 markets each generating over $100 million in annual revenue, regions where Sun Pharma has historically had lower exposure.
Organon's portfolio includes over 70 products across women's health and general medicines, providing immediate scale in categories Sun Pharma was not previously a global leader in.
Immediate Market Reaction
Markets welcomed the announcement strongly. Sun Pharmaceutical Industries shares surged on April 27, 2026, touching an intraday high of ₹1,766.65 on the NSE, a gain of 9.06%. The stock was later trading at ₹1,737, still over 7% higher than the previous close, reflecting sustained investor optimism around scale expansion, portfolio diversification, and future earnings potential.
That reaction suggests markets viewed the acquisition as more than a size increase, but many investors appear to see it as a move that could accelerate Sun Pharma's transition toward higher-value global businesses.
The Financial Side: Growth Comes With Debt
While the strategic logic is clear, the financial structure has drawn significant attention. The deal is structured as an all-cash acquisition at $14.00 per Organon share, funded through a combination of Sun Pharma's available cash and committed bank financing. Sun Pharma will also assume Organon's existing debt of $8.6 billion (against a cash balance of $574 million at year-end 2025), bringing the total enterprise value to $11.75 billion.
Organon generated $6.2 billion in revenue and $1.9 billion in adjusted EBITDA in FY25, which means the acquired business brings strong cash generation alongside the debt burden.
Post-transaction, the combined entity will carry net debt/EBITDA of approximately 2.3x, with EBITDA and cash flow set to nearly double relative to Sun Pharma's standalone position. This provides the deleveraging capacity to reduce leverage over time, though the pace will depend on integration execution, interest costs, and macro conditions.
So the deal does not automatically make the balance sheet risky, but it clearly changes Sun Pharma's financial profile. Investors will closely track deleveraging speed and how efficiently the combined business converts its expanded scale into cash flows. The transaction is expected to close in early 2027, subject to regulatory approvals and Organon shareholder approval.
| Detail | Value |
|---|---|
| Enterprise Value | $11.75 billion |
| Equity Value Per Share | $14.00 (all-cash) |
| Organon Debt Assumed | $8.6 billion |
| Organon Cash (Dec 2025) | $574 million |
| Organon FY25 Revenue | $6.2 billion |
| Organon FY25 Adj. EBITDA | $1.9 billion |
| Combined Revenue (Pro Forma) | $12.4 billion |
| Post-Deal Net Debt/EBITDA | 2.3x |
| Sun Pharma Intraday High | ₹1,766.65 (+9.06%), Apr 27, 2026 |
| Expected Close | Early 2027 |
| Source: Organon / Sun Pharma Joint Press Release, April 26, 2026; Organon FY25 Annual Results | |
What It Means for Indian Pharma
This transaction is also symbolic for India Inc. An Indian pharmaceutical company acquiring a major US-listed healthcare business of this size signals how far the domestic pharma sector has evolved. Indian companies are no longer only low-cost manufacturers or generic exporters. Some are now competing globally through scale, brands, research capability, and strategic acquisitions.
If executed well, this deal could encourage more Indian healthcare companies to think globally. For now, one thing is clear: Sun Pharma has made one of the biggest bets in Indian pharma history, and the market's initial reaction suggests investors believe it is worth making.